Samuel L Weiss, M.D. Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 48mdg/sggx, Unit 5115, Apo, AE 09464 Phone: 314-226-8148 |
News Archive
ZIOPHARM Oncology, Inc., announced today that The Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for darinaparsin (Zinaparâ„¢ or ZIO-101) designation as an orphan medicinal product for the treatment of peripheral T-cell lymphoma (PTCL).
The beneficial effect of removing cerebrospinal fluid from patients with normal pressure hydrocephalus is not mediated by reduction of ventricle volume, research suggests.
Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.
In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer's Centers for Therapeutic Innovation.
Very preterm infants are often sick and require antibiotic treatment to save their lives. However, when this form of therapy lasts for 20 months or more, it may affect the gut microbiome over the long-term in addition to its acute effects.
› Verified 4 days ago